Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

A First Step toward a New Approach to Treating Membranous Nephropathy.

Ruggenenti P, Remuzzi G.

N Engl J Med. 2019 Jul 4;381(1):86-88. doi: 10.1056/NEJMe1906666. No abstract available.

PMID:
31269372
2.

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.

Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE; ANSWER Study Organization.

Am J Kidney Dis. 2019 Apr 23. pii: S0272-6386(19)30136-2. doi: 10.1053/j.ajkd.2019.01.029. [Epub ahead of print]

PMID:
31027883
3.

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.

Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, Pisani A, Riccio E, Imbriaco M, Dugo M, Morana G, Granata A, Figuera M, Gaspari F, Carrara F, Rubis N, Villa A, Gamba S, Prandini S, Cortinovis M, Remuzzi A, Remuzzi G; ALADIN 2 Study Group.

PLoS Med. 2019 Apr 5;16(4):e1002777. doi: 10.1371/journal.pmed.1002777. eCollection 2019 Apr.

4.

C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G; EAGLE Study Group.

Am J Kidney Dis. 2019 Mar 28. pii: S0272-6386(19)30100-3. doi: 10.1053/j.ajkd.2018.12.046. [Epub ahead of print]

PMID:
30929851
5.

Erratum.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 28. pii: gfz047. doi: 10.1093/ndt/gfz047. [Epub ahead of print] No abstract available.

PMID:
30820538
6.

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.

Ruggenenti P, Trillini M, P Barlovic D, Cortinovis M, Pisani A, Parvanova A, Iliev IP, Ruggiero B, Rota S, Aparicio MC, Perna A, Peraro F, Diadei O, Gaspari F, Carrara F, Stucchi N, Martinetti D, Janez A, Gregoric N, Riccio E, Bossi AC, Trevisan R, Manunta P, Battaglia G, David S, Aucella F, Belviso A, Satta A, Remuzzi G; VALID Study Organization.

Diabetes Obes Metab. 2019 May;21(5):1177-1190. doi: 10.1111/dom.13639. Epub 2019 Feb 22.

PMID:
30793466
7.

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407.

PMID:
30753708
8.

Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.

Ruggenenti P, Remuzzi G.

Am J Nephrol. 2019;49(2):143-145. doi: 10.1159/000496275. Epub 2019 Jan 24. No abstract available.

9.

Author Correction: Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0105-4.

PMID:
30563967
10.

Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P.

Data Brief. 2018 Nov 14;21:2075-2081. doi: 10.1016/j.dib.2018.11.041. eCollection 2018 Dec.

11.

Estimated GFR: time for a critical appraisal.

Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jiménez A, de Vries APJ, Torres A, Gaspari F, Remuzzi G.

Nat Rev Nephrol. 2019 Mar;15(3):177-190. doi: 10.1038/s41581-018-0080-9. Review. Erratum in: Nat Rev Nephrol. 2018 Dec 18;:.

PMID:
30518813
12.

Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.

Spinelli L, Pisani A, Giugliano G, Trimarco B, Riccio E, Visciano B, Remuzzi G, Ruggenenti P; ALADIN-Cardiovascular Study Group.

Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.

PMID:
30509370
13.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.

Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.

Diabet Med. 2018 Oct;35(10):1375-1382. doi: 10.1111/dme.13669. Epub 2018 Jun 6.

PMID:
29781558
14.

Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience.

Gaspari F, Thakar S, Carrara F, Perna A, Trillini M, Aparicio MC, Diadei O, Ferrari S, Cannata A, Stucchi N, Ruggenenti P, Remuzzi G, Perico N.

Nephron. 2018;140(1):1-8. doi: 10.1159/000489898. Epub 2018 May 17.

PMID:
29772565
15.

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Aparicio C, Perna A, Peraro F, Rubis N, Gaspari F, Cannata A, Ferrari S, Bossi AC, Trevisan R, Parameswaran S, Chávez-Iñiguez JS, Masnic F, Seck SM, Jiamjariyaporn T, Cortinovis M, Perico L, Sharma K, Remuzzi G, Ruggenenti P, Warnock DG.

J Endocr Soc. 2018 Mar 22;2(5):420-436. doi: 10.1210/js.2017-00426. eCollection 2018 May 1.

16.

Invited letter in response to: "Is the kidney donor profile index (KDPI) universal or UNOS-specific?"

Ruggenenti P, Remuzzi G.

Am J Transplant. 2018 Apr;18(4):1033-1034. doi: 10.1111/ajt.14652. Epub 2018 Feb 3. No abstract available.

17.

Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?

Noris M, Ruggenenti P, Remuzzi G.

Am J Kidney Dis. 2017 Dec;70(6):754-757. doi: 10.1053/j.ajkd.2017.08.005. No abstract available.

PMID:
29169515
18.

Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.

Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016.

Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2.

PMID:
29104158
19.

Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study.

Ruggenenti P, Silvestre C, Boschiero L, Rota G, Furian L, Perna A, Rossini G, Remuzzi G, Rigotti P.

Am J Transplant. 2017 Dec;17(12):3159-3171. doi: 10.1111/ajt.14459. Epub 2017 Sep 15.

20.

Treatment of membranous nephropathy: time for a paradigm shift.

Ruggenenti P, Fervenza FC, Remuzzi G.

Nat Rev Nephrol. 2017 Sep;13(9):563-579. doi: 10.1038/nrneph.2017.92. Epub 2017 Jul 3. Review.

PMID:
28669992
21.

Dual renin-angiotensin system blockade for nephroprotection.

Ruggenenti P.

Nephrol Ther. 2017 Apr;13 Suppl 1:S43-S45. doi: 10.1016/j.nephro.2017.02.006.

PMID:
28577742
22.

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G.

J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.

23.

ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease.

Perico N, Ruggenenti P, Remuzzi G.

Curr Opin Pharmacol. 2017 Apr;33:34-40. doi: 10.1016/j.coph.2017.03.006. Epub 2017 May 5. Review.

PMID:
28482281
24.

Preventing nephropathy in type 2 diabetes.

Ruggenenti P.

G Ital Nefrol. 2016 Malattie Metaboliche e Rene;33(S68). pii: gin/33.S68.14. No abstract available.

25.

Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients.

Cortinovis M, Gotti E, Trillini M, Carrara F, Gaspari F, Ruggenenti P, Remuzzi G, Perico N.

Nephron. 2017;135(3):173-180. doi: 10.1159/000453671. Epub 2016 Dec 10.

PMID:
27941326
26.

Achieving remission of proteinuria in childhood CKD.

Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G.

Pediatr Nephrol. 2017 Feb;32(2):321-330. doi: 10.1007/s00467-016-3495-1. Epub 2016 Oct 4.

27.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?

Delanaye P, Melsom T, Ebert N, Bäck SE, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Gaspari F.

Clin Kidney J. 2016 Oct;9(5):700-4. doi: 10.1093/ckj/sfw071. Epub 2016 Sep 9.

28.

Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?

Delanaye P, Ebert N, Melsom T, Gaspari F, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E, Remuzzi G, Ruggenenti P, Schaeffner E, Soveri I, Sterner G, Eriksen BO, Bäck SE.

Clin Kidney J. 2016 Oct;9(5):682-99. doi: 10.1093/ckj/sfw070. Epub 2016 Aug 23.

29.

Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial.

Ruggenenti P, Abbate M, Ruggiero B, Rota S, Trillini M, Aparicio C, Parvanova A, Petrov Iliev I, Pisanu G, Perna A, Russo A, Diadei O, Martinetti D, Cannata A, Carrara F, Ferrari S, Stucchi N, Remuzzi G, Fontana L; C.RE.S.O. Study Group.

Diabetes. 2017 Jan;66(1):75-86. doi: 10.2337/db16-0607. Epub 2016 Sep 15.

30.

Progression, Remission and Regression of Chronic Renal Diseases.

Cortinovis M, Ruggenenti P, Remuzzi G.

Nephron. 2016;134(1):20-4. doi: 10.1159/000445844. Epub 2016 Apr 21. Review.

31.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

32.

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.

Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou M, Ortiz A, Ruggenenti PL, Rychlik I, Spasovski G, Rossing P.

BMJ Open. 2016 Mar 2;6(3):e010310. doi: 10.1136/bmjopen-2015-010310.

33.

Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G; SIRENA 2 Study Group.

Clin J Am Soc Nephrol. 2016 May 6;11(5):785-94. doi: 10.2215/CJN.09900915. Epub 2016 Feb 22.

34.

Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P; ALADIN Study Group.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1022-1030.e4. doi: 10.1016/j.cgh.2015.12.049. Epub 2016 Feb 1.

PMID:
26844873
35.

RAS blockade: Nephroprotection by dual RAS blockade--a welcome back.

Ruggenenti P, Remuzzi G.

Nat Rev Nephrol. 2015 Sep;11(9):507-8. doi: 10.1038/nrneph.2015.132. Epub 2015 Aug 4. No abstract available.

PMID:
26241020
36.

Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.

Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group.

Lancet Diabetes Endocrinol. 2015 May;3(5):382-91. doi: 10.1016/S2213-8587(15)00094-7.

PMID:
25943757
37.

Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?

Ruggenenti P, Remuzzi G.

Eur J Heart Fail. 2015 May;17(5):468-71. doi: 10.1002/ejhf.267. No abstract available.

38.

A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.

Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F, Remuzzi G, Ruggenenti P.

Nephron. 2015;130(1):13-20. doi: 10.1159/000381480. Epub 2015 Apr 21.

39.

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G.

J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.

40.

Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.

Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P.

Am J Nephrol. 2015;41(1):16-27. doi: 10.1159/000371728. Epub 2015 Jan 23.

PMID:
25612603
41.

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

J Am Soc Nephrol. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423. Epub 2015 Jan 14.

42.

Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.

Gentile G, Remuzzi G, Ruggenenti P.

Nephron. 2015;129(1):39-41. doi: 10.1159/000368331. Epub 2014 Dec 16. Review.

43.

Rituximab in primary membranous nephropathy: first-line therapy, why not?

Cravedi P, Remuzzi G, Ruggenenti P.

Nephron Clin Pract. 2014;128(3-4):261-9. doi: 10.1159/000368589. Epub 2014 Nov 22. Review.

44.

Novel effective drugs for diabetic kidney disease? or not?

Gentile G, Mastroluca D, Ruggenenti P, Remuzzi G.

Expert Opin Emerg Drugs. 2014 Dec;19(4):571-601. doi: 10.1517/14728214.2014.979151. Epub 2014 Nov 7. Review.

PMID:
25376947
45.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N.

J Am Soc Nephrol. 2015 May;26(5):1205-14. doi: 10.1681/ASN.2013111185. Epub 2014 Sep 5.

46.

Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab.

Marasà M, Cravedi P, Ruggiero B, Ruggenenti P.

BMJ Case Rep. 2014 Aug 25;2014. pii: bcr2014205507. doi: 10.1136/bcr-2014-205507.

47.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G.

Blood. 2014 Sep 11;124(11):1715-26. doi: 10.1182/blood-2014-02-558296. Epub 2014 Jul 18.

48.

Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease.

de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, D'Agati VD, Lamb HJ, Pongrac Barlovic D, Hojs R, Abbate M, Rodriquez R, Mogensen CE, Porrini E; ERA-EDTA Working Group Diabesity.

Lancet Diabetes Endocrinol. 2014 May;2(5):417-26. doi: 10.1016/S2213-8587(14)70065-8. Review.

PMID:
24795255
49.

Dreaming of normoglycaemia with fewer diet restrictions.

Ruggenenti P, Remuzzi G.

Lancet Diabetes Endocrinol. 2014 May;2(5):350-1. doi: 10.1016/S2213-8587(14)70002-6. Epub 2014 Jan 24. No abstract available.

PMID:
24795239
50.

Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.

Parvanova A, van der Meer IM, Iliev I, Perna A, Gaspari F, Trevisan R, Bossi A, Remuzzi G, Benigni A, Ruggenenti P; Daglutril in Diabetic Nephropathy Study Group.

Lancet Diabetes Endocrinol. 2013 Sep;1(1):19-27. doi: 10.1016/S2213-8587(13)70029-9. Epub 2013 Jun 13.

PMID:
24622263

Supplemental Content

Loading ...
Support Center